These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

571 related items for PubMed ID: 30652643

  • 1. The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease.
    Doumas M, Imprialos K, Dimakopoulou A, Stavropoulos K, Binas A, Athyros VG.
    Curr Pharm Des; 2018; 24(38):4587-4592. PubMed ID: 30652643
    [Abstract] [Full Text] [Related]

  • 2. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG, Boutari C, Stavropoulos K, Anagnostis P, Imprialos KP, Doumas M, Karagiannis A.
    Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
    [Abstract] [Full Text] [Related]

  • 3. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG, Alexandrides TK, Bilianou H, Cholongitas E, Doumas M, Ganotakis ES, Goudevenos J, Elisaf MS, Germanidis G, Giouleme O, Karagiannis A, Karvounis C, Katsiki N, Kotsis V, Kountouras J, Liberopoulos E, Pitsavos C, Polyzos S, Rallidis LS, Richter D, Tsapas AG, Tselepis AD, Tsioufis K, Tziomalos K, Tzotzas T, Vasiliadis TG, Vlachopoulos C, Mikhailidis DP, Mantzoros C.
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
    Doumas M, Imprialos K, Stavropoulos K, Athyros VG.
    Curr Vasc Pharmacol; 2019 Jun; 17(5):425-428. PubMed ID: 31418344
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options?
    Papademetriou M, Athyros VG, Geladari E, Doumas M, Tsioufis C, Papademetriou V.
    Curr Vasc Pharmacol; 2018 Jun; 16(3):254-268. PubMed ID: 28676027
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action.
    Zhang S, Ren X, Zhang B, Lan T, Liu B.
    Molecules; 2024 Apr 19; 29(8):. PubMed ID: 38675679
    [Abstract] [Full Text] [Related]

  • 11. Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?
    Paschos P, Athyros VG, Tsimperidis A, Katsoula A, Grammatikos N, Giouleme O.
    Curr Vasc Pharmacol; 2018 Apr 19; 16(3):269-275. PubMed ID: 28676018
    [Abstract] [Full Text] [Related]

  • 12. Prevalence, Diagnosis, and Treatment with 3 Different Statins of Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role?
    Sfikas G, Psallas M, Koumaras C, Imprialos K, Perdikakis E, Doumas M, Giouleme O, Karagiannis A, Athyros VG.
    Curr Vasc Pharmacol; 2021 Apr 19; 19(5):572-581. PubMed ID: 33059580
    [Abstract] [Full Text] [Related]

  • 13. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
    Athyros VG, Tziomalos K, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP.
    World J Gastroenterol; 2015 Jun 14; 21(22):6820-34. PubMed ID: 26078558
    [Abstract] [Full Text] [Related]

  • 14. Are statins 'IDEAL' for non-alcoholic fatty liver disease?
    Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP.
    Curr Med Res Opin; 2014 Feb 14; 30(2):229-31. PubMed ID: 24127654
    [Abstract] [Full Text] [Related]

  • 15. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome.
    Kargiotis K, Athyros VG, Giouleme O, Katsiki N, Katsiki E, Anagnostis P, Boutari C, Doumas M, Karagiannis A, Mikhailidis DP.
    World J Gastroenterol; 2015 Jul 07; 21(25):7860-8. PubMed ID: 26167086
    [Abstract] [Full Text] [Related]

  • 16. Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease.
    Imprialos K, Stavropoulos K, Bouloukou S, Kerpiniotis G, Karagiannis A, Doumas M.
    Curr Vasc Pharmacol; 2018 Jul 07; 16(3):276-288. PubMed ID: 28676020
    [Abstract] [Full Text] [Related]

  • 17. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.
    Caldwell S.
    Clin Mol Hepatol; 2017 Jun 07; 23(2):103-108. PubMed ID: 28494529
    [Abstract] [Full Text] [Related]

  • 18. Statins in nonalcoholic fatty liver disease and steatohepatitis: updated review.
    Nseir W, Mahamid M.
    Curr Atheroscler Rep; 2013 Mar 07; 15(3):305. PubMed ID: 23328905
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis.
    Fatima K, Moeed A, Waqar E, Atif AR, Kamran A, Rizvi H, Suri NF, Haider H, Shuja SH, Khalid M, Minhas AMK.
    Clin Res Hepatol Gastroenterol; 2022 Apr 07; 46(4):101816. PubMed ID: 34607067
    [Abstract] [Full Text] [Related]

  • 20. Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis.
    Connelly MA, Velez Rivera J, Guyton JR, Siddiqui MS, Sanyal AJ.
    Aliment Pharmacol Ther; 2020 Aug 07; 52(4):619-636. PubMed ID: 32638417
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.